Defense Therapeutics Inc. has prepared an update of the financing plans

Vancouver, BC, Canada, September 27, 2024 / IRW-Press / Defense Therapeutics Inc. (“Defence” oder das “Unternehmen”), (CSE: DTC, OTCQB: DTCFF, FWB: DTC), a canadian biopharmazeutisches Unternehmen, das Radiopharmaceutica and novel immunological immunological substances and technologies for drug development, can provide an internal update and make financial financing possible.

It may be that Sebastien Plouffe, Gründer and Director of Defense, with such a strong Wirkung, will start working as Chief Executive Officer. Mr. Plouffe has ended this phase for the current phase of the second phase, one of the efficient results of the program, the commercialization of the company and the financing of financial resources for the subdivisions. Mr. Kwin Grauer, lord of the Abwesenheit of Herrn Plouffe as interim CEO, has assumed the role of the Board of Directors. The Unternehmen thanks Herrn Grauer for his Commitment and his Bemühungen um das Wachstum von Defense.

It is possible that the new candidate has received a new appointment to his Board of Directors: Dr. Philippe Lefrançois and Mr. Arnab De as Ersatz for Dr. Moutih Rafei, from the Board of Directors, together with other CSO-bleibt, bzw. Herrn Joseph Meagher, member of the Board of Directors, became the new CFO in the new phase of Herrn Arnab. Our colleagues thanked Dr. Rafei and Herrn Meagher for their work on the Board of Directors.

Dr. Philippe Lefrançois is director of research in the Department of Dermatology at McGill University. There is an assistant professor for Medizin, Pharmacology, Therapeutik and for Surgery. There is a full-time dermatologist at the Jewish General Hospital, who is active in the multidisciplinary operation of Hautkrebskliniken and Tumorboards. There is a Prüfer at the Lady Davis Institute, where a umfassende Hautkrebs-Biobank und a Labor für vertalerische Genomik für Hautkrebs gründete. The Terry Fox Research Institute – Marathon of Hope Cancer Center Network initiative has begun for BCC and SCC. There is Mitglied des Réseau Recherche Cancer – Québec and the Québec Cancer Consortium. If you translate that there is a collaboration with biotech companies, there is a new Krebs therapeutic and diagnostic diagnosis in practice and phase I study that you can bring. Dr. Lefrançois has a Ph.D. von der Yale University and an MD from the Université de Montréal. There is absolutely no dermatology facharztausbildung at McGill. Seine Arbeit im Bereich Hautkrebs could benefit from the CDA and the AAD.

Herr Arnab De, CPA, CGMA, CMA, MBA, has done long-term research as a Führungskraft with more than 20 years of experience in Bereichen Finanzmanagement, Finanzplanung, Geschäftsoptimierung and Strategieentwicklung. There is Leiter from Resurgent Montreal Inc., a financial management assessment firm. This job is 19 years ago in the Tata Group and has a CFO position at JCAPCPL (a 50:50 JV von Tata Steel with Nippon Steel), the Automobilstähle restores, and Tata Steel Minerals Canada Ltd., where the DSO project The Gründung is a beautiful one and an investment of more than 1.5 billion. $ in Own Capital and Debts. Mr. De ist derzeit auch CFO for the business company.

“Dr. Philippe Lefrançois has conducted a research on the ARM-XTM war with the accum platform technology of defense equipment, among its potential overseas capabilities. There was a specialty of Melanome, was for Defense von Vorteil ist, that is zum Clinical Phase- I-Study with AccuTOX as Anti-krebs-Molekül in Patients with Melanoma of the Ratschläge and Erfahrung nutzen kann (see Pressemitteilung vom 8. July 2024, in the Defense is known, that is the ‘No Objection Letter from Health Canada for the phase I study conducted by Herr Arnab De is an analysis of the financing plans, Strategy and Regulations for a major Operation for the Unternehmen,” said Sebastien Plouffe, Chief Executive Officer of Defense Therapeutics.

If you want to take more than 200,000 Defense Incentive Action Options and take it to the next step, 200,000 Incentive Action Options are available and both new Directors will be expanded: 100,000 Incentive Action Options and Dr. Lefrançois and 100,000 Incentive-Aktienoptionen and Herrn De . This promotion option is as easy as possible and can last once a year before the purchase date will get a price of 0.60$ for the promotion that is running.

If you get a private company, there is a broker involvement from $3 million to $0.50 for an amount that is worth $6 million. Jede is the best of a pedigree in the Kapital des Unternehmens and has received an Aktienkaufwarrant. Your entire Warrant is entitled to receive the Inhaber zum Erwerb a sister action for a price of $ 1.00 per action for a period of 24 months after the withdrawal date.

If you are looking for an alternative, the net worth of the weiterentwicklung is used for clinical and clinical programs that use all types of working capital. It is worth making a commitment to the direction of the CSE in the future. The imprint of the Angebots is removed by writing the forms of the CSE, one of the four Monats and a Tag on the Abschlussdatum.

Uber Defense:

Defense Therapeutics is a clinical-stage research company in the biotech industry that offers a proprietary platform for companies developing the next generation of impfants and ADC products. The core of the Defense Therapeutics platform is the best in ACCUM technology, the transport of impfantige or ADCs in the input form to the Zielzellen is light. If you take the next step, you can experience improved functioning and functioning that will improve the functioning of credits and infectious diseases.

More information and further information:

Sebastien Plouffe, President, CEO and Director

Phone: (514) 947-2272

email to:[email protected]

http://www.defensetherapeutics.com

Vorsorglicher Hinweis bezüglich “zukunftsgerichteter” Informationen

This press conference has produced the best results, which can be carried out as a “zukunftsoriented outsage”. If you have become a parent, all events during that period, if you make a beginning or a division, are a fact that someone else fails to pay attention to a focused Aussagen. Zukunftsgerichtte Aussagen, if it is a historical event, it is all – jedoch nicht immer – durch Begriffe wie “erwartet”, “plant”, “antizipiert”, “glaubt”, “beabsichtigt”, “schätzt”, “prognostiziert”, ” möglich” und vergleichbare Ausdrücke or Aussagen, wonach bestimmte Ereignisse or Bedingungen eintreten “werden”, “würden”, “könnten” or “solllten”, gekennzeichnet. If the parental control is aimed at the future, then establish the guarantee for such a goal-oriented approach and the tactile ergebnisse can be found in these future-oriented children. If the factory tower leaves the company, then the most important issues in the emerging economies of the market will be viewed, the market price and the continued capital and financing activities wie allgemeine Wirtschafts-, Markt-oder Geschäftsbedingungen. Although there are more and more hinges, the only guarantee for the proper care of the body and the tactile health or care that can be taken into account can be the result of these health-related problems. The targeted publications are on the overseas, estimates and postcards of the management of the external human beings from date, and from the assessments that were made. If you do not go through the paperwork, it will not be possible to increase the independence of the business activities, if you take over the debts or management of other companies or other factories.

The CSE and the market regulatory body (which is the Begriff towards the CSE definition) do not have any responsibility for the Angemessenheit or Richtigkeit dieser Mitteilung.

The Ausgangssprache (in the Rule English), in the original text which is light, is the official, authorizing and legally binding version. These instructions can be carried out with confidence. The German language can be kürzt or jijammengefasst. There is no Verantwortung or Haftung für de Inhalt, de Direction, de Angemessenheit or de Genauigkeit dieser Übersetzung übernommen. Aus Sicht des Übersetzers stelltt die Notification keine Kauf- oder Verkaufsempfehlung dar! Bitte beachten See the English original notification at www.sedarplus.ca, www.sec.gov, www.asx.com.au/ or on the company website!

The English original notification can be found under the following link:
https://www.irw-press.at/press_html.aspx?messageID=76983
The übersetzte Notification finds the following link:
https://www.irw-press.at/press_html.aspx?messageID=76983&tr=1

SUBSCRIBE TO NEWSLETTER:

Aktuelle Pressemeldungen die Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=de&isin=CA24463V1013

Mitteilung übermittelt by IRW-Press.com. The justifiable effect is for inhalation.

Kostenloser Abdruck mit Quellenangabe erlaubt.

https://www.wallstreet-online.de/nachricht/18537622-defence-stellt-unternehmensupdate-bereit-arrangiert-finanzierung